Skip to content
2000
Volume 21, Issue 23
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Pharmacological treatment forms part of much routine psychiatric practice. Many psychotropic drugs and psychotherapies are available for treating patients with mental disorders, but considerable numbers of individuals remain troubled by incapacitating symptoms even after a succession of evidence-based treatments. In this situation, many doctors consider prescribing a psychotropic medication outside the narrow terms of its market authorisation or ‘product licence’, in an attempt to optimise clinical outcomes and increase the chance of recovery. Despite expressed concerns about potential hazards and increased physician liability, many authorities agree that using a drug outside the narrow terms of its product licence can be an important part of clinical practice. This paper illustrates the nature and extent of the use of licensed drugs for unlicensed applications in psychiatric and other medical settings, indicates potential drawbacks and hazards, and makes recommendations for a suggested process when prescribing ‘off-label’, as an appropriate part of the overall management of individual patients.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612821666150619092353
2015-07-01
2025-01-11
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612821666150619092353
Loading

  • Article Type:
    Research Article
Keyword(s): Guidance; off-label; product licence; unlicensed prescribing
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test